Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142775 | 0.75 | CA1 (0.40) | CA1CA2CA4EPHX1 | |
| SCHEMBL26090607 | 0.72 | CA1 (0.36) | CA1CA2CA4EPHX1 | |
| SCHEMBL6083265 | 0.69 | — | — | |
| SCHEMBL19180148 | 0.69 | — | — | |
| SCHEMBL19180151 | 0.69 | — | — | |
| SCHEMBL9859617 | 0.68 | CA1 (0.33) | CA1CA2CA4 | |
| SCHEMBL8948168 | 0.68 | EPHX1 (0.38) | CA1CA2CA4EPHX1 | |
| SCHEMBL2688800 | 0.68 | EPHX1 (0.38) | CA1CA2CA4EPHX1 | |
| SCHEMBL8948161 | 0.68 | EPHX1 (0.38) | CA1CA2CA4EPHX1 | |
| SCHEMBL366733 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | CYP11B2, CYP11B1, CYP1B1 | CA1 1007/4885CA2 2331/4885CA4 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.